Real-World Lung Cancer Outcomes With Targeted Drug Therapy in China
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well patients with early-stage lung cancer (that has been surgically removed) do when treated with a targeted drug called EGFR-TKI to prevent cancer from coming back. Researchers will track actual patient outcomes in China from 2023 to 2026.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer (NSCLC), which is a common type of lung cancer
- Your cancer was stage IB, II, or III (early-to-mid stage) at the time of diagnosis
- You had surgery to remove the cancer
- Your cancer has an EGFR mutation (a specific genetic change that makes it respond to targeted drugs)
- You started taking an EGFR-TKI drug (a targeted therapy pill) after surgery, between July 2023 and June 2026, to help prevent cancer recurrence
- You received treatment in China
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using a blood test to detect leftover tumor DNA after surgery can guide extra treatment for people with EGFR-mutant lung cancer. The goal is to see if starting or avoiding targeted therapy based on this test improves outcomes.
This study collects real-world information about people with lung cancer who get newer kinds of cancer drugs. It aims to understand how these innovative therapies work in everyday care and help future research.
This trial studies how traditional Chinese medicine (TCM) patterns relate to the effectiveness of EGFR-targeted pills in people with non-small cell lung cancer and an EGFR mutation. It aims to help match treatments more personally and may help improve outcomes.
This study looks back at the medical records of people in China diagnosed with early-stage lung cancer (Stage I–III) to learn more about the disease and how it is treated. It does not involve any new treatments or tests—just reviewing information that was already collected during your care.
This study uses artificial intelligence to predict how well EGFR-targeted therapy will work for people with certain lung cancers. It looks at your imaging and genetic information to help guide treatment.
This study looks at real-world information from people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to understand how patients are treated and what outcomes they have, which may help improve future care.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.